Read More
PPI use linked to worse outcomes in urothelial cancer patients treated with atezolizumab
Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with urothelial cancer treated with the immunotherapeutic atezolizumab (Tecentriq), compared with patients who did not use PPIs.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "PPI use linked to worse outcomes in urothelial cancer patients treated with atezolizumab"
Post a Comment